Duan Y - Search Results

1

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Zhang L, Xu Y, Shen J, He F, Zhang D, Chen Z, Duan Y, Sun J. Zhang L, et al. Among authors: duan y. Radiat Oncol. 2016 Apr 21;11:60. doi: 10.1186/s13014-016-0635-5. Radiat Oncol. 2016. PMID: 27097970 Free PMC article. Clinical Trial.

2

IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.

Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B, Tong Z, Chen Z. Zhao W, et al. Among authors: duan y. Oncol Rep. 2016 Mar;35(3):1483-92. doi: 10.3892/or.2015.4516. Epub 2015 Dec 24. Oncol Rep. 2016. PMID: 26706909

3

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.

Chen X, Xu Y, Liao X, Liao R, Zhang L, Niu K, Li T, Li D, Chen Z, Duan Y, Sun J. Chen X, et al. Among authors: duan y. Tumour Biol. 2016 Sep;37(9):11927-11936. doi: 10.1007/s13277-016-5052-8. Epub 2016 Apr 13. Tumour Biol. 2016. PMID: 27075472 Free PMC article.

4

Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.

Li Y, Wang Y, Niu K, Chen X, Xia L, Lu D, Kong R, Chen Z, Duan Y, Sun J. Li Y, et al. Among authors: duan y. Oncotarget. 2016 Oct 25;7(43):70535-70545. doi: 10.18632/oncotarget.12059. Oncotarget. 2016. PMID: 27655708 Free PMC article.

5

Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer.

Zhang L, Xu Z, Chen X, Duan Y, Chen Z, Sun J. Zhang L, et al. Among authors: duan y. Am J Cancer Res. 2019 Feb 1;9(2):406-414. eCollection 2019. Am J Cancer Res. 2019. PMID: 30906637 Free PMC article.

6

Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.

Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao XY, Chen X, Zhu B, Duan Y, Sun J. Zheng L, et al. Among authors: duan y. Oncologist. 2019 Aug;24(8):1031-e612. doi: 10.1634/theoncologist.2019-0285. Epub 2019 Apr 30. Oncologist. 2019. PMID: 31040256 Free PMC article. Clinical Trial.

7

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations.

Feng Y, Zhu G, Lang S, Hao P, Li G, Chen F, Zhuo W, Duan Y, Zhang A, Chen Z, Sun J. Feng Y, et al. Among authors: duan y. Front Oncol. 2021 May 28;11:659065. doi: 10.3389/fonc.2021.659065. eCollection 2021. Front Oncol. 2021. PMID: 34123814 Free PMC article.

8

Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.

Wang WD, Li R, Chen ZT, Li DZ, Duan YZ, Cao ZH. Wang WD, et al. Cancer Sci. 2005 Oct;96(10):706-12. doi: 10.1111/j.1349-7006.2005.00105.x. Cancer Sci. 2005. PMID: 16232203 Free PMC article.

9

Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.

Zhao WP, Zhu B, Duan YZ, Chen ZT. Zhao WP, et al. Oncol Rep. 2009 Jun;21(6):1405-11. doi: 10.3892/or_00000368. Oncol Rep. 2009. PMID: 19424617

10

Role of inhibitor of apoptosis protein Livin in radiation resistance in nonsmall cell lung cancer.

Sun JG, Liao RX, Zhang SX, Duan YZ, Zhuo WL, Wang XX, Wang ZX, Li DZ, Chen ZT. Sun JG, et al. Cancer Biother Radiopharm. 2011 Oct;26(5):585-92. doi: 10.1089/cbr.2011.0962. Epub 2011 Sep 1. Cancer Biother Radiopharm. 2011. PMID: 21883015

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,965 results

Search Page